Svar Life Science

April 22, 2025

Optimizing Your Bioassays: Transitioning to Second-Generation iLite® Cells

Performance Insights and Support for a Smooth Transition

We are excited to introduce our second-generation iLite® cells, designed to optimize your bioassay workflows and enhance data reliability. This blog post provides an in-depth look at the performance studies conducted on these new cell lines compared to the first-generation cells.

The second-generation iLite cells provide several advantages:

  • A significant reduction in assay time, decreasing from 18 hours to just 5 hours while maintaining the integrity of the results.
  • Improved accuracy and consistency of data through the incorporation of Renilla normalization.
  • An assay-ready format that eliminates the need for labor-intensive cell culture procedures, streamlining the workflow and reducing resource costs.

iLite® Type I IFN FAST

April 22, 2025

Optimizing Your Bioassays: Transitioning to Second-Generation iLite® Cells

Performance Insights and Support for a Smooth Transition

We are excited to introduce our second-generation iLite® cells, designed to optimize your bioassay workflows and enhance data reliability. This blog post provides an in-depth look at the performance studies conducted on these new cell lines compared to the first-generation cells.

The second-generation iLite cells provide several advantages:

  • A significant reduction in assay time, decreasing from 18 hours to just 5 hours while maintaining the integrity of the results.
  • Improved accuracy and consistency of data through the incorporation of Renilla normalization.
  • An assay-ready format that eliminates the need for labor-intensive cell culture procedures, streamlining the workflow and reducing resource costs.

iLite® Type I IFN FAST

Performance Studies on Second-Generation iLite Cells

Extensive performance studies have been conducted to validate the efficacy of our second-generation iLite Type I IFN FAST Comparing studies demonstrate similar performance on dynamic range, plate homogeneity, and day-to-day accuracy.

Fold induction

IFN I first-generation iLite

BM3049_functional

 

 

 

IFN I second-generation iLite

BM4049_functional

 

Day-to-day variation

IFN I first-generation iLite

BM3049_day-to-day

 
 
 
IFN I second-generation iLite

BM4049_day-to-day

 

The data indicates that the second-generation IFN FAST iLite cell lines can improve workflow efficiency. By providing similar reliability and reproducibility, essential for robust bioassay results - in less time!

 

Updates to iLite portfolio

As we transition to second-generation iLite Type I IFN FAST Assay Ready Cells (BM4049), we will be phasing out the following first-generation products:

  • BM3049 iLite Type IFN Assay Ready Cells
  • BM3249 iLite IFN-beta 1a (950IU/mL)
  • BM3251 iLite IFN beta 1a Nab positive control
  • BM3250 iLite Diluent D

The new iLite Type I IFN FAST cell line offers significant advancements in speed, accuracy, and overall efficiency, making them superior choices for therapeutic drug applications.

Comprehensive Customer Support During Transition

Recognizing the complexities involved in transitioning to new cell lines our dedicated support team is available for consultations and personalized assistance. Leverage our support services.

Together, we can more effectively advance your research and development efforts.
Contact us